BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15006934)

  • 1. No more equivalence trials for antibiotics in exacerbations of COPD, please.
    Miravitlles M; Torres A
    Chest; 2004 Mar; 125(3):811-3. PubMed ID: 15006934
    [No Abstract]   [Full Text] [Related]  

  • 2. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.
    Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2007; 2(3):191-204. PubMed ID: 18229559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
    Llor C; Naberan K; Cots JM; Molina J; Miravitlles M
    Int J Clin Pract; 2004 Oct; 58(10):937-44. PubMed ID: 15587773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
    Herath SC; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotics in acute exacerbations of COPD: the good, the bad and the ugly.
    Boersma WG
    Eur Respir J; 2012 Jul; 40(1):1-3. PubMed ID: 22753830
    [No Abstract]   [Full Text] [Related]  

  • 6. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M; Anzueto A
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
    Wilson R; Allegra L; Huchon G; Izquierdo JL; Jones P; Schaberg T; Sagnier PP;
    Chest; 2004 Mar; 125(3):953-64. PubMed ID: 15006954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
    Miravitlles M; Llor C; Naberan K; Cots JM; Molina J;
    Respir Med; 2005 Aug; 99(8):955-65. PubMed ID: 15950136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.
    Wilson R; Macklin-Doherty A
    Expert Rev Respir Med; 2012 Nov; 6(5):481-92. PubMed ID: 23113693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI).
    Chuchalin A; Zakharova M; Dokic D; Tokić M; Marschall HP; Petri T
    BMC Pulm Med; 2013 Jan; 13():5. PubMed ID: 23343427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study.
    Miravitlles M; Anzueto A; Ewig S; Legnani D; Stauch K
    Ther Adv Respir Dis; 2009 Dec; 3(6):267-77. PubMed ID: 19880426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute exacerbated chronic bronchitis. Antibiotics in comparison].
    MMW Fortschr Med; 2003 Oct; 145(40):57. PubMed ID: 14603610
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis].
    Miravitlles M; Molina J; Brosa M
    Arch Bronconeumol; 2007 Jan; 43(1):22-8. PubMed ID: 17257560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying patients at risk of late recovery (≥ 8 days) from acute exacerbation of chronic bronchitis and COPD.
    Anzueto A; Miravitlles M; Ewig S; Legnani D; Heldner S; Stauch K
    Respir Med; 2012 Sep; 106(9):1258-67. PubMed ID: 22749710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining factors in the prescription of moxifloxacin in exacerbations of chronic bronchitis in the primary-care setting.
    Miravitlles M; Llor C
    Clin Drug Investig; 2007; 27(2):95-104. PubMed ID: 17217314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.
    Wilson R; Anzueto A; Miravitlles M; Arvis P; Faragó G; Haverstock D; Trajanovic M; Sethi S
    Int J Chron Obstruct Pulmon Dis; 2011; 6():373-83. PubMed ID: 21760724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.
    Wilson R; Anzueto A; Miravitlles M; Arvis P; Alder J; Haverstock D; Trajanovic M; Sethi S
    Eur Respir J; 2012 Jul; 40(1):17-27. PubMed ID: 22135277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxifloxacin: a review of its use in the management of bacterial infections.
    Keating GM; Scott LJ
    Drugs; 2004; 64(20):2347-77. PubMed ID: 15456331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S; Decramer M
    Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative assessment of fluoroquinolones efficacy in the treatment of patients with infectious exacerbation of chronic obstructive bronchitis].
    Iudina LV; Snezhko VI; Rachko IuV
    Lik Sprava; 2004; (1):34-7. PubMed ID: 17051710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.